AAIC26: Biogen stock drops after unveiling tau-targeting ASO data

Data released by Biogen at AAIC26 appears to have spooked investors, with an 8.17% drop in share price. Data released by Biogen at AAIC26 appears to have spooked investors, with an 8.17% drop in share price. Biogen said that the 60mg cohort saw greater benefit than either of the115mg cohorts. Credit: Tada Images / Shutterstock.com Biogen’s stock has dropped after it released mixed data on its tau-targeting investigational antisense oligonucleotide (ASO), compounding a previous announcement of the trial failing to meet its primary endpoint. Data from the randomised, double blind, Phase II CELIA study (NCT05399888) was presented at the Alzheimer’s…

Source: Clinical Trials Arena